Compare CVS Health Corp (CVS) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Taskus Inc — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.49B), while Taskus Inc trades at $7.99 (market cap $723.41M). The key difference: CVS Health Corp is far larger — about 155.5× Taskus Inc's market cap, and CVS Health Corp pays a 3.02% dividend while Taskus Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Taskus Inc for 34 Days on average.
| CVS | TASK | |
|---|---|---|
Market Cap | $112.49B | $723.41M |
Volume | 8,467,392 | 201,303 |
Sector | Health | Technology |
52-Week High | $110.60 | $14.69 |
52-Week Low | $70.08 | $4.57 |
Typical Hold Time | 83 Days | 34 Days |
Enterprise Value | $174.83B | $1.09B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
TaskUs trades at $8.01, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with revenue growth to $1.18B in 2025 and net income margin expansion to 8.75%. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.29 expected, driven by AI services growth offsetting Trust & Safety declines.
The stock appears undervalued with P/E of 6.8 and P/S of 0.6, supported by analyst consensus target of $9.33 representing 16% upside. Key risks include labor cost pressures and client concentration, while AI segment growth at 26% provides upside catalyst. Institutional ownership increased with Dimensional Fund Advisors raising stake by 12.8% in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
